Woo Sik Yu1, Hee Suk Jung1, Jin Gu Lee1, Dae Joon Kim1, Kyung Young Chung1, Chang Young Lee1. 1. 1 Department of Thoracic Surgery, Armed Forces Capital Hospital, Seongnam-si, Kyunggi-do, Republic of Korea ; 2 Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: Perioperative bleeding concerns have led to the general recommendation that antiplatelet agents (APAs) be discontinued 7-10 days preoperatively, but this could increase the risk of perioperative cardiovascular events. This retrospective study aimed to evaluate the safety of APA continuation during thoracoscopic surgery for lung cancer. METHODS: Between January 2009 and February 2015, 164 patients taking APAs underwent curative resection. Comparisons were conducted between two groups: preoperatively interrupted APA administration (group I, n=106) and continued APA administration (group N, n=58). RESULTS: Group N had a significantly higher revised cardiac risk index (rCRI) (P=0.001). Lobectomy was performed in the majority of patients [95 (89.6%) in group I; 52 (89.7%) in group N]. There were no significant differences in intraoperative outcomes, such as the thoracotomy conversion rate, operating time, intraoperative transfusion, and amount of blood loss during the operation, or postoperative outcomes, such as postoperative bleeding and thrombotic complications, postoperative transfusions, and operative mortality. Within group N, the patients taking aspirin + clopidogrel (n=11) had significantly greater postoperative bleeding (P=0.005), and more postoperative transfusions (P=0.003) and chest tube drainage over a 3-day period (P=0.049) compared with other antiplatelet regimens. CONCLUSIONS: Continued use of APAs during thoracoscopic surgery for lung cancer could be safely done in patients at high risk of cardiac or thrombotic events. However, in patients administered aspirin + clopidogrel, it may be the best to continue aspirin only because of an increased risk of postoperative bleeding and transfusion requirements.
BACKGROUND: Perioperative bleeding concerns have led to the general recommendation that antiplatelet agents (APAs) be discontinued 7-10 days preoperatively, but this could increase the risk of perioperative cardiovascular events. This retrospective study aimed to evaluate the safety of APA continuation during thoracoscopic surgery for lung cancer. METHODS: Between January 2009 and February 2015, 164 patients taking APAs underwent curative resection. Comparisons were conducted between two groups: preoperatively interrupted APA administration (group I, n=106) and continued APA administration (group N, n=58). RESULTS: Group N had a significantly higher revised cardiac risk index (rCRI) (P=0.001). Lobectomy was performed in the majority of patients [95 (89.6%) in group I; 52 (89.7%) in group N]. There were no significant differences in intraoperative outcomes, such as the thoracotomy conversion rate, operating time, intraoperative transfusion, and amount of blood loss during the operation, or postoperative outcomes, such as postoperative bleeding and thrombotic complications, postoperative transfusions, and operative mortality. Within group N, the patients taking aspirin + clopidogrel (n=11) had significantly greater postoperative bleeding (P=0.005), and more postoperative transfusions (P=0.003) and chest tube drainage over a 3-day period (P=0.049) compared with other antiplatelet regimens. CONCLUSIONS: Continued use of APAs during thoracoscopic surgery for lung cancer could be safely done in patients at high risk of cardiac or thrombotic events. However, in patients administered aspirin + clopidogrel, it may be the best to continue aspirin only because of an increased risk of postoperative bleeding and transfusion requirements.
Entities:
Keywords:
Lung cancer surgery; adult; thoracoscopy/VATS
Authors: T H Lee; E R Marcantonio; C M Mangione; E J Thomas; C A Polanczyk; E F Cook; D J Sugarbaker; M C Donaldson; R Poss; K K Ho; L E Ludwig; A Pedan; L Goldman Journal: Circulation Date: 1999-09-07 Impact factor: 29.690
Authors: Neal Stuart Gerstein; Peter Mark Schulman; Wendy Hawks Gerstein; Timothy Randal Petersen; Isaac Tawil Journal: Ann Surg Date: 2012-05 Impact factor: 12.969
Authors: Emmanouil I Kapetanakis; Diego A Medlam; Steven W Boyce; Elizabeth Haile; Peter C Hill; Mercedes K C Dullum; Ammar S Bafi; Kathleen R Petro; Paul J Corso Journal: Eur Heart J Date: 2005-02-21 Impact factor: 29.983
Authors: J Mantz; C M Samama; F Tubach; P J Devereaux; J-P Collet; P Albaladejo; B Cholley; R Nizard; J Barré; V Piriou; N Poirier; A Mignon; S Schlumberger; D Longrois; F Aubrun; M E Farèse; P Ravaud; P G Steg Journal: Br J Anaesth Date: 2011-08-27 Impact factor: 9.166
Authors: Giuseppe G L Biondi-Zoccai; Marzia Lotrionte; Pierfrancesco Agostoni; Antonio Abbate; Massimiliano Fusaro; Francesco Burzotta; Luca Testa; Imad Sheiban; Giuseppe Sangiorgi Journal: Eur Heart J Date: 2006-10-19 Impact factor: 29.983
Authors: A Oscarsson; A Gupta; M Fredrikson; J Järhult; M Nyström; E Pettersson; B Darvish; H Krook; E Swahn; C Eintrei Journal: Br J Anaesth Date: 2010-03 Impact factor: 9.166
Authors: Michael W A Chu; Steve R Wilson; Richard J Novick; Larry W Stitt; MacKenzie A Quantz Journal: Ann Thorac Surg Date: 2004-11 Impact factor: 4.330